Jim Simons Vanda Pharmaceuticals Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 3,566,425 shares of VNDA stock, worth $16.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

3,566,425

Previous 3,853,799 7.46%

Holding current value

$16.3 Million

Previous $18.5 Million 11.32%

% of portfolio

0.03%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$4.31 - $5.13 $1.24 Million - $1.47 Million	-287,374 Reduced 7.46%	3,566,425 $16.4 Million
Q4 2024 Feb 13, 2025	SELL	$4.41 - $5.46 $695,558 - $861,167	-157,723 Reduced 3.93%	3,853,799 $18.5 Million
Q3 2024 Nov 13, 2024	SELL	$4.61 - $6.34 $472,999 - $650,503	-102,603 Reduced 2.49%	4,011,522 $18.8 Million
Q2 2024 Aug 09, 2024	SELL	$3.91 - $6.5 $631,465 - $1.05 Million	-161,500 Reduced 3.78%	4,114,125 $23.2 Million
Q1 2024 May 13, 2024	BUY	$3.47 - $4.61 $2.06 Million - $2.74 Million	594,500 Added 16.15%	4,275,625 $17.6 Million
Q4 2023 Feb 13, 2024	BUY	$3.38 - $4.58 $1.4 Million - $1.9 Million	415,100 Added 12.71%	3,681,125 $15.5 Million
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $658,940 - $1.01 Million	153,958 Added 4.95%	3,266,025 $14.1 Million
Q2 2023 Aug 11, 2023	BUY	$5.9 - $6.95 $1.04 Million - $1.23 Million	176,842 Added 6.02%	3,112,067 $20.5 Million
Q1 2023 May 12, 2023	BUY	$6.18 - $7.99 $283,044 - $365,942	45,800 Added 1.59%	2,935,225 $19.9 Million
Q4 2022 Feb 13, 2023	SELL	$6.87 - $10.96 $2.79 Million - $4.45 Million	-405,808 Reduced 12.32%	2,889,425 $21.4 Million
Q3 2022 Nov 14, 2022	SELL	$9.44 - $11.76 $3.22 Million - $4.01 Million	-341,200 Reduced 9.38%	3,295,233 $32.6 Million
Q2 2022 Aug 12, 2022	BUY	$9.31 - $11.84 $3.98 Million - $5.07 Million	427,819 Added 13.33%	3,636,433 $39.6 Million
Q1 2022 May 13, 2022	SELL	$10.84 - $16.55 $39,024 - $59,580	-3,600 Reduced 0.11%	3,208,614 $36.3 Million
Q4 2021 Feb 11, 2022	SELL	$15.69 - $21.14 $1.1 Million - $1.48 Million	-70,108 Reduced 2.14%	3,212,214 $50.4 Million
Q3 2021 Nov 12, 2021	SELL	$15.35 - $21.27 $439,010 - $608,322	-28,600 Reduced 0.86%	3,282,322 $56.3 Million
Q2 2021 Aug 13, 2021	SELL	$15.71 - $21.51 $5.9 Million - $8.08 Million	-375,558 Reduced 10.19%	3,310,922 $71.2 Million
Q1 2021 May 13, 2021	SELL	$13.42 - $20.28 $4.08 Million - $6.16 Million	-303,923 Reduced 7.62%	3,686,480 $55.4 Million
Q4 2020 Feb 10, 2021	SELL	$9.77 - $13.81 $3.82 Million - $5.39 Million	-390,519 Reduced 8.91%	3,990,403 $52.4 Million
Q3 2020 Nov 13, 2020	BUY	$9.32 - $12.02 $1.41 Million - $1.82 Million	151,100 Added 3.57%	4,380,922 $42.3 Million
Q2 2020 Aug 13, 2020	BUY	$9.66 - $12.02 $3.67 Million - $4.57 Million	380,168 Added 9.88%	4,229,822 $48.4 Million
Q1 2020 May 14, 2020	BUY	$7.5 - $16.8 $2.97 Million - $6.66 Million	396,542 Added 11.48%	3,849,654 $39.9 Million
Q4 2019 Feb 13, 2020	BUY	$12.38 - $17.47 $3.03 Million - $4.28 Million	244,772 Added 7.63%	3,453,112 $56.7 Million
Q3 2019 Nov 13, 2019	BUY	$12.27 - $15.79 $5.03 Million - $6.48 Million	410,290 Added 14.66%	3,208,340 $42.6 Million
Q2 2019 Aug 12, 2019	BUY	$13.37 - $18.85 $3.12 Million - $4.4 Million	233,300 Added 9.1%	2,798,050 $39.4 Million
Q1 2019 May 14, 2019	BUY	$17.59 - $31.05 $939,306 - $1.66 Million	53,400 Added 2.13%	2,564,750 $47.2 Million
Q4 2018 Feb 13, 2019	BUY	$18.97 - $31.47 $47.6 Million - $79 Million	2,511,350 New	2,511,350 $65.6 Million

Others Institutions Holding VNDA

# of Institutions

159

Shares Held

44.7M

Call Options Held

64.8K

Put Options Held

562K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $259M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account